We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+19.93%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$239M
Cap. Flow
+$174M
Cap. Flow %
13.43%
Top 10 Hldgs %
54.55%
Holding
35
New
10
Increased
17
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$60.8M
2
NUVL
Nuvalent
NUVL
+$42.4M
3
VIR icon
Vir Biotechnology
VIR
+$25.5M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$23M
5
ACLX
Arcellx
ACLX
+$22.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$97.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.1M
3
KROS icon
Keros Therapeutics
KROS
+$39.7M
4
ASND icon
Ascendis Pharma A/S
ASND
+$37.6M
5
ARGX icon
argenx
ARGX
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$10.8B
$19.6M 1.52%
+85,000
New +$23M
VRNA
27
DELISTED
Verona Pharma
VRNA
$18.9M 1.46%
893,861
-68,500
-7% -$1.46M
MLTX icon
28
MoonLake Immunotherapeutics
MLTX
$1.57B
$18.9M 1.46%
+369,615
New +$9.95M
THRX
29
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$18.2M 1.41%
1,950,327
+445,000
+30% +$4.39M
KURA icon
30
Kura Oncology
KURA
$800M
$10.6M 0.82%
+1,004,908
New +$11.9M
ASND icon
31
Ascendis Pharma A/S
ASND
$16B
– –
-350,866
Closed -$37.6M
BIIB icon
32
Biogen
BIIB
$30B
– –
-349,593
Closed -$97.2M
KROS icon
33
Keros Therapeutics
KROS
$199M
– –
-930,752
Closed -$39.7M
PSTX
34
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-1,072,410
Closed -$3.3M
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-281,969
Closed -$57.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Paradigm Biocapital Advisors held 35 positions worth $1.29B, up 23% from $1.06B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Paradigm Biocapital Advisors deployed $174M of net new capital in Q2 2023, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 283,605 shares worth $61.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $15.3M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 283,605 shares worth $61.5M.
  • Paradigm Biocapital Advisors added most to Arcellx in Q2 2023, an estimated $22.5M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2023 reduction was argenx, cutting an estimated $15.3M.
  • Paradigm Biocapital Advisors fully exited Biogen in Q2 2023, selling an estimated $97.2M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 55% of its $1.29B portfolio in Q2 2023.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q2 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 23% quarter-over-quarter to $1.29B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.